This spring, UCB engaged the Atlanta community at the 2018 Atlanta Science Festival with a booth called “How the Canine Mind Helps People with Severe Diseases.” The festival is a two-week celebration of science offering more than 100 events at locations throughout metro Atlanta. UCB participated at the expo event held in Piedmont Park on March 24. 

Luiz Miguel Camargo, Ph.D., UCB’s Director of Innovation Networks, was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign talking about his work and dedication to advancing science to find solutions. 

Dr. Victor Sloan, UCB’s VP & Development Strategy Lead (immunology), was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign. Learn more about Dr. Sloan’s work and his motivation to find groundbreaking solutions.

Today, we announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),¹ an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

UCB to expand epilepsy portfolio with strategic acquisition of Midazolam Nasal Spray from Proximagen

April is Parkinson’s Awareness Month. To honor those living with Parkinson’s disease (PD), we’re spreading awareness about the disease and sharing some of our favorite stories of inspiration.

As the U.S. affiliate of UCB, a global biopharmaceutical company, we are excited to be relaunching UCB-USA.com and a blog with news on UCB in the U.S.

UCBCares^® is UCB, Inc.'s single source solution center in the U.S. dedicated to providing exceptional caring experiences and solutions for all incoming inquiries to UCB from patients, caregivers, and healthcare providers.

UCB strengthens research capabilities with acquisition of Element Genomics, a Duke University biotech spin-off

CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.